Phesgo and Tecentriq Performance and Approvals
VENTANA FOLR1 (FOLR1-2.1) RxDx assay
First FDA approved FOLR1 companion diagnostic test for ovarian cancer
Roche
First Line
Treatment
Testing
chemo or
chemo + bevacizumab
Progression for 80% of patients
•
VENTANA FOLR1 (FOLR1-2.1)
RxDx Assay
35% of patients³ FOLR1 positive
mirvetuximab soravtansine-gyxn
Second Line
Treatment
(ELAHERE®)
322k estimated cases of ovarian cancer worldwide
(2021)1
First FDA-approved IHC companion diagnostic test for
determining FRa protein expression in epithelial
ovarian cancer (EOC)
Enables pathologists to identify patients who may be
eligible for a new therapy, ELAHERE Ⓡ 2
•
Runs on automated BenchMark series of instruments
1 Clarivate Epidemiology Report: Ovarian Cancer, Clarivate Plc. Accessed 04/07/2023; 2 Results from the SORAYA clinical study demonstrated -32% of eligible patients showed a partial or complete response to ELAHERE therapy;
3 The VENTANA FOLR1 (FOLR-2.1) RxDx Assay was used as part of the SORAYA clinical study to identify patients whose tumors were positive for FRa protein (≥ 75% of viable tumor cells with moderate (2+) and/or strong (3+)
membrane staining). In this study, approximately 35% of ovarian cancer patients expressed high levels of FRa (defined as ≥ 75% tumour cells staining with 2+/3+ intensity) and were considered FRα-positive by the VENTANA FOLR1
(FOLR1-2.1) RxDx Assay. Roche. VENTANA FOLR1 (FOLR-2.1) RxDx Assay. US Package Insert. 2022. Matulonis UA, et al. Abstract LB4. Presented at Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer. March
18-21, 2022.
41View entire presentation